2025-05-26-Bernstein-美国生物技术_筛选残余_低于现金水平的生物技术公司的当前格局和历史回报_19页_1mb

Biotech Investment Report Summary: Sub-Cash Companies

As of 27 May 2025, there is a surge in interest in investing in "sub-cash" biotech companies, marked by a record high of 133 such firms, comprising over 20% of all listed biotechs.

Highlighting key findings:

• Historical performance: Data shows that investing blindly in sub-cash companies yields positive returns in 57% of periods when comparing to the XBI index, though median returns underperform, indicating skewed data where positive surprises from clinical trials often drive exceptional stock performance.

• Investment strategy viability: A strategy focused on acquiring sub-cash companies (currently trading below cash value) appears promising on paper, with the success heavily reliant on achieving "big wins" driven primarily by positive clinical trial results or data releases.

• Market dynamics: Since 2020, an overabundance of biotech IPOs saw the industry face consequences as many trading below their cash reserves struggle. This has spurred investors to explore merger/dissolution or consolidation outcomes.

• Strategic alternatives: Notable companies like Keros Therapeutics, Atea, and others are exploring strategies like reverse mergers, partnerships, or outright acquisition for value creation. Elsewhere, several firms that recently wrapped up strategic reviews have seen acquisitions take place, such as Allakos being acquired by Tim Tang's Concentra Biosciences.

• Investment implications: Despite the apparent strategy viability, effective implementation faces challenges: scaling difficulties, sustained cash burn until a value creation event, and resistant boards. However, the report serves as a useful starting point for further research.

Specific companies like Allakos and Kronos Bio are the latest targets of acquisition by Tim Tang's Concentra, highlighting a trend in private shell acquisitions gaining traction. Many others remain in active consideration of strategic shifts but still face hurdles in execution.